Hepatitis Monthly

Published by: Kowsar

A Survey on the Prevalence of Depression in Blood Donors with Hepatitis C in Shiraz

Leila Kasraian 1 , * , Neda Negarestani 2 , Mohammad Hossein Karimi 3 and Sahar Dehbidi 4
Authors Information
1 Associate Professor, Community Medicine Specialist, Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Shiraz, IR Iran
2 Assistant Professor, Psychiatrist, Manager of Consultation Center, Iranian Blood Transfusion Research Center, Shiraz, IR Iran
3 PhD of Immunology, Director, President, Iranian Blood Transfusion Research Center, Shiraz Blood Transfusion Organization, Shiraz, IR Iran
4 Master of Cellular and Molecular Science, Shiraz, IR Iran
Article information
  • Hepatitis Monthly: November 01, 2016, 16 (11); e31080
  • Published Online: November 6, 2016
  • Article Type: Research Article
  • Received: December 7, 2015
  • Revised: July 27, 2016
  • Accepted: October 5, 2016
  • DOI: 10.5812/hepatmon.31080

To Cite: Kasraian L, Negarestani N, Karimi M H, Dehbidi S. A Survey on the Prevalence of Depression in Blood Donors with Hepatitis C in Shiraz, Hepat Mon. 2016 ; 16(11):e31080. doi: 10.5812/hepatmon.31080.

Copyright © 2016, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Alavian SM. Hepatitis C infection in Iran; A review article. Arch Clin Infect Dis. 2009; 4(1): 47-59
  • 2. Martin V, Bernhardsgrutter R, Goebel R, Steinert T. The use of mechanical restraint and seclusion in patients with schizophrenia: a comparison of the practice in Germany and Switzerland. Clin Pract Epidemiol Ment Health. 2007; 3: 1[DOI][PubMed]
  • 3. Barboza KC, Salinas LM, Sahebjam F, Jesudian AB, Weisberg IL, Sigal SH. Impact of depressive symptoms and hepatic encephalopathy on health-related quality of life in cirrhotic hepatitis C patients. Metab Brain Dis. 2016; 31(4): 869-80[DOI][PubMed]
  • 4. Ersche KD, Fletcher PC, Lewis SJ, Clark L, Stocks-Gee G, London M, et al. Abnormal frontal activations related to decision-making in current and former amphetamine and opiate dependent individuals. Psychopharmacology (Berl). 2005; 180(4): 612-23[DOI][PubMed]
  • 5. Kiecolt-Glaser JK,, Glaser R. Depression and immune function: central pathways to morbidity and mortality . J Psychosomat Res. 2002; 53(4): 873-6
  • 6. Ong JP, Younossi ZM. Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia. Cleve Clin J Med. 2004; 71 Suppl 3-21[PubMed]
  • 7. Franke L, Therstappen E, Schlosser B, Biermer M, Berg T, Schafer M, et al. A Preliminary Study on the Relationship between Platelet Serotonin Transporter Functionality, Depression, and Fatigue in Patients with Untreated Chronic Hepatitis C. Depress Res Treat. 2014; 2014: 821381[DOI][PubMed]
  • 8. Evon DM, Simpson KM, Esserman D, Verma A, Smith S, Fried MW. Barriers to accessing care in patients with chronic hepatitis C: the impact of depression. Aliment Pharmacol Ther. 2010; 32(9): 1163-73[DOI][PubMed]
  • 9. Carta MG, Hardoy MC. Why a new online open access journal in the field of clinical and epidemiological research in mental health? Clin Pract Epidemiol Ment Health. 2005; 1(1): 1[DOI][PubMed]
  • 10. Alipour A, Nouri N. A study on reliability and validity of the depression-happiness scale in justice's staff of isfahan city. Q J Fundament Ment Health.
  • 11. Dieperink E, Ho SB, Thuras P, Willenbring ML. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics. 2003; 44(2): 104-12[PubMed]
  • 12. Grothe KB, Dutton GR, Jones GN, Bodenlos J, Ancona M, Brantley PJ. Validation of the Beck Depression Inventory-II in a low-income African American sample of medical outpatients. Psychol Assess. 2005; 17(1): 110-4[DOI][PubMed]
  • 13. Dwight MM, Kowdley KV, Russo JE, Ciechanowski PS, Larson AM, Katon WJ. Depression, fatigue, and functional disability in patients with chronic hepatitis C. J Psychosom Res. 2000; 49(5): 311-7[PubMed]
  • 14. Golden J, O'Dwyer AM, Conroy RM. Depression and anxiety in patients with hepatitis C: prevalence, detection rates and risk factors. Gen Hosp Psychiatry. 2005; 27(6): 431-8[DOI][PubMed]
  • 15. Malhotra S, Kaur N, Kumar P, Bhatia M, Hans C. Hepatitis C and Depression. Delhi Psychiatr J. 2011; 14(1): 143-8
  • 16. Harris M. Injecting, infection, illness: abjection and hepatitis C stigma. Body Soc. 2009; 15(4): 33-51
  • 17. Weissenborn K, Tryc AB, Heeren M, Worthmann H, Pflugrad H, Berding G, et al. Hepatitis C virus infection and the brain. Metab Brain Dis. 2009; 24(1): 197-210[DOI][PubMed]
  • 18. Golub ET, Latka M, Hagan H, Havens JR, Hudson SM, Kapadia F, et al. Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck Depression Inventory. J Urban Health. 2004; 81(2): 278-90[PubMed]
  • 19. Thomson BJ, Finch RG. Hepatitis C virus infection. Clin Microbiol Infect. 2005; 11(2): 86-94[DOI][PubMed]
  • 20. Loftis JM, Hauser P. Hepatitis C in patients with psychiatric disease and substance abuse: screening strategies and comanagement models of care. Curr Hepat Rep. 2003; 2(3): 93-100
  • 21. Khantzian EJ, Treece C. DSM-III psychiatric diagnosis of narcotic addicts. Recent findings. Arch Gen Psychiatry. 1985; 42(11): 1067-71[PubMed]
  • 22. Vabo IL, Ferreira LE, Pace FH. Depressive Episode Incidence in Patients with Chronic Hepatitis C Treated with Pegylated Interferon and Ribavirin. Arq Gastroenterol. 2016; 53(1): 20-4[DOI][PubMed]
  • 23. Kanwal F, Gralnek IM, Hays RD, Zeringue A, Durazo F, Han SB, et al. Health-related quality of life predicts mortality in patients with advanced chronic liver disease. Clin Gastroenterol Hepatol. 2009; 7(7): 793-9[DOI][PubMed]
  • 24. Adams MH, Lovejoy TI, Turk DC, Dobscha SK, Hauser P, Morasco BJ. Pain-related anxiety mediates the relationship between depressive symptoms and pain interference in veterans with hepatitis C. Gen Hosp Psychiatry. 2015; 37(6): 533-7[DOI][PubMed]
  • 25. Bonaccorso S, Marino V, Biondi M, Grimaldi F, Ippoliti F, Maes M. Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord. 2002; 72(3): 237-41[PubMed]
  • 26. Rowan PJ. Does prophylactic antidepressant treatment boost interferon-alpha treatment completion in HCV? World J Virol. 2013; 2(4): 139-45[DOI][PubMed]
  • 27. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001; 344(13): 961-6[DOI][PubMed]
  • 28. Smith KJ, Norris S, O'Farrelly C, O'Mara SM. Risk factors for the development of depression in patients with hepatitis C taking interferon-alpha. Neuropsychiatr Dis Treat. 2011; 7: 275-92[DOI][PubMed]
  • 29. Sockalingam S, Abbey SE. Managing depression during hepatitis C treatment. Can J Psychiatry. 2009; 54(9): 614-25[PubMed]
  • 30. Evon DM, Ramcharran D, Belle SH, Terrault NA, Fontana RJ, Fried MW, et al. Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study. Am J Gastroenterol. 2009; 104(12): 2949-58[DOI][PubMed]
  • 31. Pavlovic Z, Delic D, Maric NP, Vukovic O, Jasovic-Gasic M. Depressive symptoms in patients with hepatitis C treated with pegylated interferon alpha therapy: a 24-week prospective study. Psychiatr Danub. 2011; 23(4): 370-7[PubMed]
  • 32. Nesic Z, Delic D, Prostran M, Stojanovic R, Vuckovic S, Todorovic Z. [Psychiatric adverse effects induced by recombinant interferon alfa in patients with chronic hepatitis C]. Med Pregl. 2004; 57(5-6): 219-26[PubMed]
  • 33. Martin-Santos R, Diez-Quevedo C, Castellvi P, Navines R, Miquel M, Masnou H, et al. De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C. Aliment Pharmacol Ther. 2008; 27(3): 257-65[DOI][PubMed]
  • 34. Raison CL, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, Jacobson IM, et al. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry. 2005; 66(1): 41-8[PubMed]
  • 35. Schaefer M, Schmidt F, Neumer R, Scholler G, Schwarz M. Interferon-alpha, cytokines and possible implications for mood disorders. Bipolar Disord. 2002; 4 Suppl 1: 111-3[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments